Here's Why Ocugen Is Skyrocketing On Monday

Motley Fool2021-09-14

There's both good and bad news for this troubled coronavirus vaccine biotech. What happened Ocugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

wallence82
2021-09-14
wallence82
Like
Alkid
2021-09-14
Alkid
Interesting
StarGate
2021-09-14
StarGate
Risk involved and the gain cannot be ignored
jo88
2021-09-14
jo88
Like pls
- Alkid:
  Done
- Holla:
  Ok
Shibing
2021-09-14
Shibing
Ok
- Huntsilencer:
  up
MC8989
2021-09-14
MC8989
Okk

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1133790240?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-14 15:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133790240","market":"us","top_or_hot":-1,"title":"Here's Why Ocugen Is Skyrocketing On Monday","media":"Motley Fool","content":"<div>\n<p>There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Ocugen Is Skyrocketing On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Ocugen Is Skyrocketing On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-14 15:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/13/heres-why-ocugen-is-skyrocketing-today/","article_id":"1133790240","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133790240","pubTimestamp":1631605138,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(N","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"这就是为什么Ocugen在周一飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"There's both good and bad news for this troubled coronavirus vaccine biotech.\nWhat happened\nOcugen(NASDAQ:OCGN) shares surged 15.8% on heavy volume to $8.28 apiece on Monday, sources told Indian news agency Asian News International that the World Health Organization will likely grant emergency use listing for Indian coronavirus vaccine Covaxin this week.\nSo what\nAn EUL from the WHO would give credibility for more regulatory agencies around the world to approve Covaxin. In clinical trials, the vaccine demonstrated 77.8% effectiveness against symptomatic COVID-19, including those cases caused by variant strains. India-based Bharat Biotech owns the worldwide commercialization rights to Covaxin except in the U.S. and Canada, where it licensed them to Ocugen.\nIMAGE SOURCE: GETTY IMAGES.\nNow what\nWhile the WHO development is good news, keep in mind that Ocugen is a research-stagebiotechwith no late-stage pipeline candidates, and it does not even own Covaxin. To make matters worse, the company has been seeking a Biologic License Application with the U.S. Food and Drug Administration for approval since June, which would take a very long time and also need an additional clinical trial to support the application. If that weren't enough, half of all profits from this venture would go to Bharat Biotech.\nThe company's market cap has soared to $1.5 billion -- even though it only plans to sell 100 million doses of Covaxin in the states. At a time when there is an abundance of approved alternatives available, it's best to be careful around Ocugen's stock.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":886409716,"gmtCreate":1631611184635,"gmtModify":1631885576638,"author":{"id":"3564307944903490","authorId":"3564307944903490","name":"wallence82","avatar":"https://static.tigerbbs.com/dea005ab03386f13fa25c505b9a3221a","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3564307944903490","authorIdStr":"3564307944903490"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/886409716","repostId":1133790240,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":886540504,"gmtCreate":1631608874108,"gmtModify":1631890135703,"author":{"id":"3574044380631135","authorId":"3574044380631135","name":"Alkid","avatar":"https://static.tigerbbs.com/d584ca72b32575d58fab92034b2973bc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574044380631135","authorIdStr":"3574044380631135"},"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/886540504","repostId":1133790240,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":886523972,"gmtCreate":1631607102996,"gmtModify":1631891344126,"author":{"id":"3586990023332519","authorId":"3586990023332519","name":"StarGate","avatar":"https://static.tigerbbs.com/9db084b2eae373a6cc56043329defb07","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586990023332519","authorIdStr":"3586990023332519"},"htmlText":"Risk involved and the gain cannot be ignored&nbsp;","listText":"Risk involved and the gain cannot be ignored&nbsp;","text":"Risk involved and the gain cannot be ignored","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/886523972","repostId":1133790240,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":886562510,"gmtCreate":1631606743530,"gmtModify":1631889601032,"author":{"id":"3555382377663213","authorId":"3555382377663213","name":"jo88","avatar":"https://static.tigerbbs.com/3f3f7cfe71e85f286a9274876c16ebf2","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3555382377663213","authorIdStr":"3555382377663213"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/886562510","repostId":1133790240,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5864102,"gmtCreate":1631608925597,"gmtModify":1631889601045,"authorId":3574044380631135,"author":{"id":3574044380631135,"idStr":"3574044380631135","authorId":3574044380631135,"name":"Alkid","avatar":"https://static.tigerbbs.com/d584ca72b32575d58fab92034b2973bc","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":886562510,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5863838,"gmtCreate":1631606821850,"gmtModify":1631889601031,"authorId":3565687171198207,"author":{"id":3565687171198207,"idStr":"3565687171198207","authorId":3565687171198207,"name":"Holla","avatar":"https://static.tigerbbs.com/c0b0e402ff8043410cc67ffccbfe2174","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":886562510,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":886588732,"gmtCreate":1631605678426,"gmtModify":1631890460984,"author":{"id":"3554626415127931","authorId":"3554626415127931","name":"Shibing","avatar":"https://static.tigerbbs.com/cc800279dcdb8bb992f0c97452095c4f","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3554626415127931","authorIdStr":"3554626415127931"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/886588732","repostId":1133790240,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5863758,"gmtCreate":1631606125970,"gmtModify":1631890460985,"authorId":3583029437333652,"author":{"id":3583029437333652,"idStr":"3583029437333652","authorId":3583029437333652,"name":"Huntsilencer","avatar":"https://static.tigerbbs.com/9b69d6b5db7ba7ec92be9ac8c5c5705c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":886588732,"type":1,"supId":0,"prevId":0,"content":"<u>up</u>","text":"<u>up</u>","html":"<u>up</u>"}],"langContent":"EN"},{"id":886581823,"gmtCreate":1631605481962,"gmtModify":1631888614234,"author":{"id":"3562482274169298","authorId":"3562482274169298","name":"MC8989","avatar":"https://static.tigerbbs.com/58eed81f9dc051542d8569ad3065f505","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3562482274169298","authorIdStr":"3562482274169298"},"htmlText":"Okk","listText":"Okk","text":"Okk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/886581823","repostId":1133790240,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":29,"commentSize":8,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133790240"}